Marquette Asset Management LLC Grows Stake in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Marquette Asset Management LLC increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 13.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,908 shares of the company’s stock after purchasing an additional 1,191 shares during the period. Marquette Asset Management LLC’s holdings in Fulgent Genetics were worth $215,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in FLGT. Park West Asset Management LLC raised its holdings in Fulgent Genetics by 23.1% during the 4th quarter. Park West Asset Management LLC now owns 424,783 shares of the company’s stock valued at $12,280,000 after buying an additional 79,649 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Fulgent Genetics by 98.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,792 shares of the company’s stock worth $1,883,000 after buying an additional 42,998 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Fulgent Genetics by 43.0% during the first quarter. BNP Paribas Financial Markets now owns 16,779 shares of the company’s stock valued at $364,000 after purchasing an additional 5,043 shares during the period. Quantbot Technologies LP boosted its position in Fulgent Genetics by 165.0% in the first quarter. Quantbot Technologies LP now owns 16,071 shares of the company’s stock worth $349,000 after purchasing an additional 10,007 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in Fulgent Genetics by 8.1% during the first quarter. Empowered Funds LLC now owns 109,167 shares of the company’s stock valued at $2,369,000 after buying an additional 8,225 shares during the last quarter. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Price Performance

Shares of FLGT stock opened at $20.53 on Wednesday. Fulgent Genetics, Inc. has a one year low of $18.91 and a one year high of $30.68. The company’s fifty day moving average price is $22.59 and its 200-day moving average price is $21.58. The company has a market capitalization of $614.34 million, a price-to-earnings ratio of -3.69 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings data on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. The business had revenue of $71.03 million for the quarter, compared to analysts’ expectations of $69.07 million. During the same period in the prior year, the firm earned ($0.33) EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities research analysts expect that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current fiscal year.

Insider Activity at Fulgent Genetics

In related news, CEO Ming Hsieh sold 2,313 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total transaction of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at $16,147,088.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders sold 4,324 shares of company stock worth $98,717. Company insiders own 31.76% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.